Novo Nordisk announced today that Wegovy® (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and ...
A robust and systematic approach is key to ensuring that people living with heart failure with preserved ejection fraction (HFpEF) receive a timely and accurate diagnosis and guideline-based therapies ...